Thursday, July 03, 2008
An FDA panel voted 14-2 in favor of requiring experimental diabetes drugs to show that they don't increase heart or cardiovascular risks.
This is bad news for diabetes drugs in the pipeline to be submitted for approval like AstraZeneca and Bristol-Myers Squibb's drug saxagliptin.
Read the story from the Wall Street Journal here.
This vote come on the heels of the Avandia controversy last year.The drug Avandia came under scrutiny for supposed increased heart risks in patients taking the drug. Read our experts' coverage of the FDA's Avandia hearing here.
